银丹心脑通软胶囊联合依折麦布治疗高脂血症的临床研究

目的探讨银丹心脑通软胶囊联合依折麦布治疗高脂血症的临床效果。方法选取2016年8月—2017年10月南阳市卧龙区第一人民医院收治的高脂血症患者90例,随机分为对照组(45例)和治疗组(45例)。对照组口服依折麦布片,10 mg/次,1次/d。治疗组在对照组基础上口服银丹心脑通软胶囊,3粒/次,3次/d。两组患者均连续治疗8周。观察两组患者临床疗效,同时比较治疗前后两组患者中医症候积分、血脂指标、血管内皮功能指标和不良反应情况。结果治疗后,对照组临床有效率为73.33%,显著低于治疗组的91.11%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者中医证候积分明显降低(P0.05),且治疗组中医证候积分明显低于对照组(P0.05)。治疗后,两组患者总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平显著下降(P0.05),高密度脂蛋白胆固醇(HDL-C)水平显著升高(P0.05),且治疗组TC、TG、LDL-C和HDL-C水平明显优于对照组(P0.05)。治疗后,两组患者内皮素-1(ET-1)水平明显降低(P0.05),一氧化氮(NO)水平明显升高(P0.05),且治疗组ET-1和NO水平明显优于对照组(P0.05)。治疗期间,治疗组不良反应发生率为6.98%,明显低于对照组的27.91%,两组药物不良反应发生率比较差异具有统计学意义(P0.05)。结论银丹心脑通软胶囊联合依折麦布治疗高脂血症可显著提高临床疗效,明显改善患者血管内皮功能,有效调节患者血脂水平,且安全性较高。

Clinical study on Yindan Xinnaotong Soft Capsules combined with ezetimibe in treatment of hyperlipidemia

Objective To investigate the effect of Yindan Xinnaotong Soft Capsules combined with ezetimibe in treatment of hyperlipidemia. Methods Patients (90 cases) with hyperlipidemia in the First people''s Hospital of Wolong District of Nanyang from August 2016 to October 2017 were randomly divided into control (45 cases) and treatment (45 cases) groups. Patients in the control group were po administered with Ezetimibe Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Yindan Xinnaotong Soft Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the TCM syndrome scores, the blood lipid indexes, the vascular endothelial function indexes, adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 73.33%, which was significantly lower than 91.11% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the the TCM syndrome scores in two groups were significantly decreased (P<0.05), and the scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the TC, TG and LDL-C levels in two groups were significantly decreased (P<0.05), but HDL-C levels were significantly increased (P<0.05), and the TC, TG, LDL-C and HDL-C levels in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the ET-1 levels in two groups were significantly decreased (P<0.05), but NO levels were significantly increased (P<0.05), and the ET-1 and NO levels in the treatment group were significantly better than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 6.98%, which was significantly lower than 27.91% in the control group, with significant difference between two groups (P<0.05). Conclusion Yindan Xinnaotong Soft Capsules combined with ezetimibe in treatment of hyperlipidemia can significantly improve the clinical efficacy, significantly improve the vascular endothelial function, effectively regulate the blood lipid level, and has high safety.